HIV-induced changes in T cell signaling pathways

Journal of Immunology

Volumn 180, Issue 10, 2008, Pages 6490-6500

  Schweneker, Marc ^a,d   Favre, David ^a   Martin, Jeffrey N ^c   Deeks, Steven G ^b   McCune, Joseph M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN FRANCISCO GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; INTERLEUKIN 2; IONOMYCIN; PHORBOL 13 ACETATE 12 MYRISTATE; T LYMPHOCYTE RECEPTOR; ANTIRETROVIRUS AGENT; CROSS LINKING REAGENT; LEUKOCYTE ANTIGEN; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DISEASE COURSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; MAJOR CLINICAL STUDY; OXIDATION REDUCTION REACTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN PHOSPHORYLATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; VIRUS LOAD; BIOSYNTHESIS; BLOOD; DRUG EFFECT; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOLOGY; MALE; PHOSPHORYLATION; T LYMPHOCYTE; VIROLOGY;

ANTI-RETROVIRAL AGENTS; ANTIGENS, CD; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-LINKING REAGENTS; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV LONG-TERM SURVIVORS; HUMANS; MALE; PHOSPHORYLATION; RNA, VIRAL; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 45549103855     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.180.10.6490     Document Type: Article

References (65)

1. Baier, M., A. Werner, N. Bannert, K. Metzner, and R. Kurth. 1995. HIV suppression by interleukin-16. Nature 378: 563.
2. + T cells. Science 270: 1811-1815.
3. + T-cells: function and response to HIV infection. Curr. HIV Res. 2: 23-37.
4. Koup, R. A., J. T. Safrit. Y. Cao, C. A. Andrews, G. McLeod, W. Borkowsky C. Farthing, and D. D. Ho. 1994. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68: 4650-4655.
5. + T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc. Natl. Acad. Sci. USA 92: 2308-2312.
6. Ogg, G. S., X. Jin, S. Bonhoeffer, P. R. Dunbar, M. A. Nowak, S. Monard, J. P. Segal, Y. Cao, S. L. Rowland-Jones, V. Cerundolo, et al. 1998. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279: 2103-2106.
7. Plata, F., B. Autran, L. P. Martins, S. Wain-Hobson, M. Raphael, C. Mayaud, M. Denis, J. M. Guillon, and P. Debre. 1987. AIDS virus-specific cytotoxic T lymphocytes in lung disorders. Nature 328: 348-351.
8. Walker, B. D., S. Chakrabarti, B. Moss, T. J. Paradis, T. Flynn, A. G. Durno, R. S. Blumberg, J. C. Kaplan, M. S. Hirsch, and R. T. Schooiey. 1987. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature 328: 345-348.
9. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234: 1563-1566.
10. Kalams, S. A. and B. D. Walker. 1998. The critical need for CD4 help in main; taining effective cytotoxic T lymphocyte responses. J. Exp. Med. 188: 2199-2204.
11. Hellerstein, M., M. B. Hanley, D. Cesar, S. Siler, C. Papageorgopoulos, E. Wieder, D. Schmidt, R. Hoh, R. Neese, D. Macallan, et al. 1999. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat. Med. 5: 83-89.
12. + T-cell depiction in HIV disease. Nature 410: 974-979.
13. + T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J. Exp. Med. 187: 1295-1303.
14. + T cell turnover. Science 274: 1543-1547.
15. + T cell repopulation of lymphoid tissues after treatment of HIV-1 infection. Proc. Natl. Acad. Sci. USA 95: 1154-1159.
16. + cell numbers and clinical staging. J. Clin. Invest. 84: 1892-1899.
17. Gruters, R. A., F. G. Terpstra, R. De Jong, C. J. Van Noesel, R. A. Van Lier, and F. Miedema. 1990. Selective loss of T cell functions in different stages of HIV infection. Early loss of anli-CD3-induced T cell proliferation followed by decreased anti-CD3-induccd cytotoxic T lymphocyte generation in AIDS-related complex and AIDS. Eur. J, Immunol. 20: 1039-1044.
18. Imami, N., A. Pires, G. Hardy, J. Wilson. B. Gazzard, and F. Gotch. 2002. A balanced type 1/type 2 response is associated with long-term nonprogrcssive human immunodeficiency virus type 1 infection. J. Virol. 76: 9011-9023.
19. Kryworuchko, M., V. Pasquier, H. Keller, D. David, C. Goujard, J. Gilquin, J. P. Viard, M. Joussemet, J. F. Delfraissy, and J. Theze. 2004. Defective inter-leukin-2-dependent STAT5 signalling in CDS T lymphocytes from HIV-positive patients: restoration by antiretroviral therapy. AIDS 18: 421-426.
20. Musey, L. K., J. N. Krieger, J. P. Hughes, T. W. Schacker, L. Corey, and M. J. McElrath. 1999. Early and persistent human immunodeficiency virus type 1 (HIV-l)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J. Infect. Dis. 180: 278-284.
21. + T lymphocyte granules in lymphoid tissue during acute human immunodeficiency virus type 1 infection. J. Infect. Dis. 185: 1355-1358.
22. + T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Sled. 192: 63-75.
23. + cells arc the predominant T cells in normal humans that synthesize the β-chemokine macrophage inflammatory protein-1β. Proc. Natl. Acad. Sci. USA 98: 9283-9288.
24. + T cells vary in differentiation phenotype in different persistent virus infections. Nat. Med. 8: 379-385.
25. Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi. S. Fleury, M. Lipp, et al. 2001. Skewed maturation of memory HIV-specific CDS T lymphocytes. Nature 410: 106-111.
26. Trimble, L. A., L. W. Kam, R. S. Friedman, Z. Xu, and J. Lieberman. 2000. CD3ζ and CD28 down-modulation on CD8 T cells during viral infection. Blood 96: 1021-1029.
27. Trimble, L. A., and J. Lieberman. 1998. Circulating CDS T lymphocytes in human immunodeficiency virus-infected individuals have impaired function and downmodulate CD3 ζ, the signaling chain of the T-cell receptor complex. Blood 91:585-594.
28. Lieberman, J., P. Shankar, N. Manjunath, and J. Andersson. 2001. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 98: 1667-1677.
29. + T-cell maturation: CD27 might provide a clue. Trends Immunol. 23: 586-591.
30. Roos, M. T., M. Prins, M. Koot, F. de Wolf, M. Bakker, R. A. Coutinho, F. Miedema, and P. T. Schellekens. 1998. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS. AIDS 12: 1745-1751.
31. Schellekens, P. T., M. T. Roos, F. De Wolf, J. M. Lange, and F. Miedema. 1990. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency vi-rus-1 (HIV-1)-infected men. J. Clin. Immunol. 10: 121-127.
32. Cayota, A., F. Vuillier, J. Siciliano, and G. Dighiero. 1994. Defective protein tyrosine phosphorylation and altered levels of p59fyn and p561ck in CD4 T cells from HIV-1 infected patients. Int. Immunol. 6: 611-621.
33. Stefanova, I., M. W. Saville, C. Peters, F. R. Cleghom, D. Schwartz, D. J. Venzon, K. J. Weinhold, N. Jack, C. Bartholomew, W. A. Blattner, et al. 1996. HIV infection-induced posttranslational modification of T cell signaling molecules associated with disease progression. J. Clin. Invest. 98: 1290-1297.
34. + T cells in pathogenic versus apathogenic simian immunodeficiency virus infection. J. Virol. 75: 11298-11306.
35. Gale, M. J., Jr., J. A. Ledbetler, G. L. Schieven, M. Jonker, W. R. Morton, R. E. Benveniste, and E. A. Clark. 1990. CD4 and CD8 T cells from SIV-infected macaques have defective signaling responses after perturbation of either CD3 or CD2 receptors. Int. Immunol. 2: 849-858.
36. Farber, D. L., O. Acuto, and K. Bottomly. 1997. Differential T cell receptor-mediated signaling in naive and memory CD4 T cells. Eur. J. Immunol. 27: 2094-2101.
37. + T cell function in the course of human immunodeficiency virus infection: gradual decline of both naive and memory allorcactive T cells. J. Clin. Invest. 94: 1947-1952.
38. + effector and memory T cell generation. Nat. Immunol. 4: 835-842.
39. Krutzik, P. O., and G. P. Nolan. 2003. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 55: 61-70.
40. Perez, O. D., P. O. Krutzik, and G. P. Nolan. 2004. Flow cytometric analysis of kinase signaling cascades. Methods Mol. Biol. 263: 67-94.
41. Perez, O. D., and G. P. Nolan. 2002. Simultaneous measurement of multiple active kinase states using polychromatic flow cytometry. Nat. Biotechnol. 20: 155-162.
42. Barber, D. L., E. J. Wherry, D. Masopust, B. Zhu, J. P. Allison, A. H. Sharpe, G. J. Freeman, and R. Ahmed. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
43. Day, C. L., D. E. Kaufmann. P. Kiepiela, J. A. Brown, E. S. Moodley, S. Reddy, E. W. Mackey, J. D. Miller, A. J. Leslie, C. DePierres, et al. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443: 350-354.
44. Freeman. G. J., E. J. Wherry, R. Ahmed, and A. H. Sharpe. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203: 2223-2227.
45. + T cell survival in HIV infection. J. Exp. Med. 203: 2281-2292.
46. + T cells leads to reversible immune dysfunction. Nat. Med. 12: 1198-1202.
47. Sommers, C. L., C. S. Park, J. Lee, C. Feng, C. L. Fuller, A. Grinberg, J. A. Hildebrand, E. Lacana, R. K. Menon, E. W. Shores, et al. 2002. A LAT mutation that inhibits T cell development yet induces lymphoproliferation. Science 296: 2040-2043.
48. + T-cell changes independent of viral load. Blood 104: 942-947.
49. Hazenberg, M. D., S. A. Otto, B. H. van Benthem, M. T. Roos, R. A. Coutinho, J. M. Lange, D. Hamann, M. Prins, and F. Miedema. 2003. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17: 1881-1888.
50. Giorgi, J. V., R. H. Lyles, J. L. Matud, T. E. Yamashita, J. W. Mellors, L. E. Hultin, B. D. Jamieson, J. B. Margolick, C. R. Rinaldo, Jr., J. P. Phair, and R. Detels. 2002. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J. Acquired Immune Deftc. Syndr. 29: 346-355.
51. + T cell function by the HIV envelope protein, gpl20. J. Immunol. 141: 3715-3717.
52. Mittler, R. S., and M. K. Hoffmann. 1989. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation. Science 245: 1380-1382.
53. Goldman, F., J. Crablree, C. Hollenback, and G. Koretzky. 1997. Sequestration of p56(lck) by gpl20, a model for TCR desensitization. J. Immunol. 158: 2017-2024.
54. Juszczak, R. J., H. Turchin, A. Truneh, J. Culp, and S. Kassis. 1991. Effect of human immunodeficiency virus gp120 glycoprotein on the association of the protein tyrosine kinase p561ck with CD4 in human T lymphocytes. J. Biol. Chem. 266: 11176-11183.
55. Sheppard, K. A., L. J. Fitz, J. M. Lee. C. Benander, J. A. George, J. Wooters, Y. Qiu, J. M. Jussif, L. L. Carter, C. R. Wood, and D. Chaudhary. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ζ signalo-some and downstream signaling to PKCθ FEBS Lett. 574: 37-41.
56. low thymocytes in the HIV type 1-infected thymus. J. Immunol. 169: 2788-2796.
57. Keir, M. E., C. A. Stoddart. V. Linquist-Stepps, M. E. Moreno, and J. M. McCune. 2002. IFN-α secretion by type 2 predendritic cells up-regulates MHC class I in the HIV-1-infected thymus. J. Immunol. 168: 325-331.
58. Bovolenta, C., L. Camorali, A. L. Lorini, S. Ghezzi, E. Vicenzi, A. Lazzarin, and G. Poli. 1999. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 94: 4202-4209.
59. Droge, W., K. Schulze-Osthoff, S. Mihm, D. Gaiter, H. Schenk, H. P. Eck, S. Roth, and H. Gmunder. 1994. Functions of glutathione and glutathione disul-fide in immunology and immunopalhology. FASEB J. 8: 1131-1138.
60. Lim, J. S., H. P. Eck, H. Gmunder, and W. Droge. 1992. Expression of increased immunogenicity by thiol-releasing tumor variants. Cell. Immunol. 140: 345-356.
61. Staal, F. J., M. T. Anderson, G. E. Staal, L. A. Herzenberg, C. Gitler, and L. A. Herzenberg. 1994. Redox regulation of signal transduction: tyrosine phosphorylation and calcium influx. Proc. Natl. Acad. Sci. USA 91: 3619-3622.
62. Staal, F. J., M. Roederer, D. M. Israelski, J. Bubp, L. A. Mole, D. McShane, S. C. Deresinski, W. Ross, H. Sussman, P. A. Raju, et al. 1992. Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals. AIDS Res. Hum. Relroviruses 8: 305-311.
63. Kanner, S. B., T. J. Kavanagh, A. Grossmann, S. L. Hu, J. B. Bolen, P. S. Rabinovitch, and J. A. Ledbetter. 1992. Sulfhydryl oxidation down-regulates T-cell signaling and inhibits tyrosine phosphorylation of phospholipase C γ 1. Proc. Natl. Acad. Sci. USA 89: 300-304.
64. Atkuri, K. R., J. J. Mantovani, L. A. Herzenberg, and L. A. Herzenberg. 2007. N-Acetylcysteine: a safe antidote for cysteine/glutathione deficiency. Curr. Opin. Pharmacol. 7: 355-359.
65. Irish, J. M., R. Hovland, P. O. Krutzik. O. D. Perez, O. Bruserud, B. T. Gjertsen, and G. P. Nolan. 2004. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 118: 217-228.